Nereus Pharmaceuticals

Nereus Pharmaceuticals, Inc. is a biotechnology company that has been pioneering marine microbiology to develop advanced treatments for cancer, infections, and inflammation since 1998. The company focuses on discovering and developing therapeutics for oncology, infectious diseases, and inflammation, leveraging its marine microbiology technologies to identify and formulate drug candidates. In the field of oncology, Nereus Pharmaceuticals has developed notable drug candidates such as NPI-2358, a tumor vascular disrupting agent targeting solid tumors, and NPI-0052, a proteasome inhibitor aimed at treating solid tumors, lymphomas, and multiple myeloma. The company is headquartered in San Diego, California. In June 2010, Nereus Pharmaceuticals secured a significant $20.00M Series E investment from prominent investors including Advent International, HBM Healthcare Investments, Alta Partners, Forward Ventures, Astellas Venture Management, Roche Venture Fund, and Pacific Venture Group. This investment reflects the confidence of reputable venture capital firms in the potential of Nereus Pharmaceuticals' innovative approach to drug development within the biotechnology and healthcare industries.